
Cambrian BioPharma
Cambrian Biopharma: A DisCo advancing modern healthcare with breakthrough medicines to enhance healthspan and quality of life.
- 30
- Company
- New York, NY, USUnited States

Cambrian Biopharma: A DisCo advancing modern healthcare with breakthrough medicines to enhance healthspan and quality of life.
cambrianbio.comCrawled Oct 14, 2026
The company comprises scientists and business experts who aim to improve quality of life worldwide.
The company is committed to a world where people can remain physically and mentally healthy throughout their first century of life. It believes everyone deserves a long, healthy, fulfilling life free from age-related chronic diseases.
Cambrian Bio is a clinical-stage drug development company developing therapeutics that will redefine healthcare in the 21st century.
Cambrian is developing a raft of new companies and therapies to extend healthy lifespan, bringing proven scientific and organizational expertise to exceptional research teams worldwide.
Cambrian develops a drug that replicates some physiological effects of exercise in animal models. Early research suggests the compound may improve muscle function and metabolic health without physical activity. The therapy targets pathways linked to aging and age-related decline.
Jun 2026STATNews article
Cambrian Bio reports Phase 1b clinical results showing ATX-304, the first AMPK network activator, achieves statistically significant improvements in liver fat, visceral adipose tissue, triglycerides, adiponectin levels, and resting metabolic rate in adults with obesity and prediabetes. The data mark the first clinical evidence of human translation for an AMPK Network Activator. The findings were presented at the American Diabetes Association’s 86th Scientific Sessions.
Jun 2026Cambrian BioNews article
TechCrunch makes recordings of its TechCrunch Live founder-and-investor interviews available as podcasts and on YouTube. The featured conversations include Persona co-founder Rick Song and Index Ventures’ Mark Goldberg on identity verification, Cambrian BioPharma co-founder James Peyer and Future Ventures’ Maryanna Saenko on drug development, and founders and investors from ClassDojo, Habi, and Oma Fertility. Topics include AI, longevity biotech, edtech, uncertainty, and fertility care.
May 2023TechCrunchNews article
Cambrian Bio unveils **Amplifier Therapeutics**, a new company targeting **AMPK activation**, a highly pursued drug target in aging research. The initiative aims to develop therapies by leveraging this metabolic pathway, which plays a key role in cellular energy regulation and longevity.
Mar 2023Longevity.TechnologyNews article